199 results on '"M. Haubitz"'
Search Results
2. Persistierende Anämie nach Nierentransplantation bei einem 36-jährigen Patienten – eine ungewöhnliche Ursache
- Author
-
G. Köhler, M. Mäske, S. Graf, P. Kostrewa, M. Haubitz, and P. Benöhr
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,Internal Medicine ,Medicine ,030212 general & internal medicine ,030204 cardiovascular system & hematology ,business - Abstract
Bei einem 36-jahrigen Patienten wurde eine allogene Nierentransplantation durchgefuhrt (Match 1‑1‑0, Zytomegalievirus [CMV] Donor [D] +/Empfanger −, hohes Risiko). Elf Jahre zuvor war es zu einer Dialysepflichtigkeit im Rahmen einer bioptisch gesicherten tubulointerstitiellen Nephritis gekommen. Nach Transplantation ereignete sich im Verlauf des initialen stationaren Aufenthalts ein sukzessiver Hamoglobinabfall von 11,4 g/dl auf 7,3 g/dl. Initial war dies erklart durch die stattgehabte Nierentransplantation und einer chronisch fibrosierende Antrumgastritis mit Erosionen. Trotz wiederholter Transfusion von Erythrozytenkonzentraten bestand eine refraktare Anamie, weswegen sich der Patient mehrfach in unserer Klinik zur weiteren Diagnostik und Therapie vorstellte. Bei Darstellung von Riesenproerythroblasten im Knochenmark sowie dem quantitativen Nachweis von Parvovirus B19 (>900 Mio. IU/ml DNA-Replikationen) imponierte das Bild einer virusassoziierten Aplasie der Erythropoese. Eine intravenose Immunglobulinapplikation wurde etabliert und zeigte einen langfristigen therapeutischen Erfolg.
- Published
- 2020
3. [57/m-Dialysis patient presenting for allogeneic kidney transplant : Preparation for the medical specialist examination: part 152]
- Author
-
C, Bauer-Büntzel and M, Haubitz
- Subjects
Renal Dialysis ,Hematopoietic Stem Cell Transplantation ,Humans ,Kidney Failure, Chronic ,Kidney ,Kidney Transplantation - Published
- 2022
4. Initiative of the government to improve the structure of organ donation : Hope for many patients waiting for a donor organ
- Author
-
M. Haubitz, L. Weber, Martin Zeier, U. Kunzendorf, Hermann Haller, Gunter Wolf, Rudolf P. Wüthrich, Juergen Floege, Kai-Uwe Eckardt, Burkhard Tönshoff, Uwe Heemann, Christiane M. Erley, Danilo Fliser, Jens Lutz, Thorsten Feldkamp, Joachim Hoyer, Oliver Witzke, W. Kleophas, and F. Schweda
- Subjects
Nephrology ,medicine.medical_specialty ,Transplant surgery ,business.industry ,Internal medicine ,General surgery ,Medizin ,Medicine ,business - Published
- 2019
5. [Persistent anemia after kidney transplantation in a 36-year-old male patient-an unusual cause]
- Author
-
M, Mäske, M, Haubitz, S, Graf, G, Köhler, P, Kostrewa, and P, Benöhr
- Subjects
Adult ,Male ,Parvoviridae Infections ,Renal Dialysis ,Parvovirus B19, Human ,Humans ,Red-Cell Aplasia, Pure ,Kidney Transplantation - Abstract
An allogeneic kidney transplantation (match 1‑1‑0, cytomegalovirus, CMV, donor, D, +/recipient, R, - high risk) was performed in a 36-year-old patient. The patient was on dialysis due to a tubulointerstitial nephritis confirmed by biopsy 11 years previously. Posttransplantation there was a gradual decrease in the hemoglobin (Hb) level from 11.4 g/dl to 7.3 g/dl during the initial hospitalization period. Initially this was explained by the kidney transplantation and chronic fibrosing antral gastritis with erosions. Despite repeated transfusion of red cell concentrates, a refractory anemia persisted, which is why the patient presented several times at our clinic for further diagnosis and treatment. The presence of giant erythroblasts in the bone marrow and quantitative detection of parvovirus B19 (900 million IU/ml DNA replications) was consistent with a virus-associated red cell aplasia. Intravenous immunoglobulin administration was established and showed long-term therapeutic success.Bei einem 36-jährigen Patienten wurde eine allogene Nierentransplantation durchgeführt (Match 1‑1‑0, Zytomegalievirus [CMV] Donor [D] +/Empfänger −, hohes Risiko). Elf Jahre zuvor war es zu einer Dialysepflichtigkeit im Rahmen einer bioptisch gesicherten tubulointerstitiellen Nephritis gekommen. Nach Transplantation ereignete sich im Verlauf des initialen stationären Aufenthalts ein sukzessiver Hämoglobinabfall von 11,4 g/dl auf 7,3 g/dl. Initial war dies erklärt durch die stattgehabte Nierentransplantation und einer chronisch fibrosierende Antrumgastritis mit Erosionen. Trotz wiederholter Transfusion von Erythrozytenkonzentraten bestand eine refraktäre Anämie, weswegen sich der Patient mehrfach in unserer Klinik zur weiteren Diagnostik und Therapie vorstellte. Bei Darstellung von Riesenproerythroblasten im Knochenmark sowie dem quantitativen Nachweis von Parvovirus B19 (900 Mio. IU/ml DNA-Replikationen) imponierte das Bild einer virusassoziierten Aplasie der Erythropoese. Eine intravenöse Immunglobulinapplikation wurde etabliert und zeigte einen langfristigen therapeutischen Erfolg.
- Published
- 2020
6. Akutes auf chronisches Nierenversagen – ein ungewöhnlicher Fall
- Author
-
M. Haubitz, K. Amann, and P. Benöhr
- Subjects
030203 arthritis & rheumatology ,0301 basic medicine ,Nephrology ,medicine.medical_specialty ,business.industry ,General surgery ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Transplant surgery ,Internal medicine ,medicine ,business ,Angiology - Published
- 2016
7. Vaskulitiden
- Author
-
M. Haubitz
- Subjects
Nephrology - Published
- 2015
8. Therapierefraktäre arterielle Hypertonie und prominentes Sternum bei einer 77-jährigen Patientin
- Author
-
J. Hildebrand, A. Hertel, P. Benöhr, and M. Haubitz
- Subjects
Gynecology ,medicine.medical_specialty ,Prominent sternum ,business.industry ,Internal medicine ,Treatment outcome ,Internal Medicine ,medicine ,Hypertension diagnosis ,Hepatology ,business - Abstract
Wir berichten uber eine 77-jahrige Patientin, die mit therapierefraktarer arterieller Hypertonie eingewiesen wurde. Die aufgrund eines Phaochromozytoms in der Anamnese bestimmten Katecholamine waren erhoht, zudem zeigte sich in der Metaiodbenzylguanidin(MIBG)-Szintigraphie ein positiver Herd im vorderen Mediastinum, computertomographisch im Corpus sterni gelegen. Histologisch fand sich hier eine Metastase des Phaochromozytoms, sodass das Corpus sterni exstirpiert wurde. Aktuell ist die Patientin ohne Hinweis auf ein Rezidiv.
- Published
- 2014
9. Tryptophan immunoadsorption for the treatment of autoimmune encephalitis
- Author
-
Annette Baumgartner, Frank Hoffmann, H. Topka, Stefanie Schmidt, S. Ehrlich, Oliver Stich, T. Neumann-Haefelin, W. Köhler, C. Fassbender, R. Klingel, M. Haubitz, A. Kraft, and Christian Dohmen
- Subjects
Adult ,Male ,Young Adult ,Therapeutic approach ,Antigen ,Modified Rankin Scale ,medicine ,Humans ,Immunoadsorption ,Immunosorbent Techniques ,gamma-Aminobutyric Acid ,Aged ,Autoantibodies ,Retrospective Studies ,Anti-N-Methyl-D-Aspartate Receptor Encephalitis ,Autoimmune encephalitis ,Glutamate Decarboxylase ,business.industry ,Neurological status ,Tryptophan ,Autoantibody ,Middle Aged ,medicine.disease ,Cytoskeletal Proteins ,Treatment Outcome ,Neurology ,Immunology ,Encephalitis ,Female ,Neurology (clinical) ,business - Abstract
Background and purpose Detection of autoantibodies against neuronal surface antigens and their correlation with the pattern and severity of symptoms led to the definition of new autoimmune-mediated forms of encephalitis and was essential for the initiation of immunotherapies including plasma exchange. The elimination of autoantibodies using selective immunoadsorption (IA) is a pathophysiologically guided therapeutic approach but has not yet been evaluated in a separate analysis. Methods A retrospective analysis was performed of patients with autoimmune encephalitis who were treated with tryptophan IA in six neurological clinics between 2009 and 2013. The modified Rankin scale (mRS) was used to evaluate neurological status before and after IA. Results Data on 13 patients were documented. Twelve patients were positive for specific autoantibodies (NMDA-R, GABA, GAD, Lgl1). Patients received a series of a median of six IA treatments. Median mRS of all patients was 3.0 before IA and 2.0 after IA (P
- Published
- 2014
10. Seltene Erkrankungen
- Author
-
H. Haller and M. Haubitz
- Subjects
Nephrology - Published
- 2019
11. Neue therapeutische Möglichkeiten bei den Vaskulitiden
- Author
-
M. Haubitz
- Subjects
Nephrology ,medicine.medical_specialty ,Transplant surgery ,business.industry ,General surgery ,Internal medicine ,Medicine ,business ,Angiology - Published
- 2015
12. Lupusnephritis
- Author
-
M. Haubitz
- Subjects
Biological Products ,Rheumatology ,Antibodies, Monoclonal ,Humans ,Lupus Nephritis ,Immunosuppressive Agents - Abstract
Bei einem systemischen Lupus erythematodes muss bei 30–90% der Patienten im Verlauf mit einer renalen Beteiligung gerechnet werden. Diese ist entscheidend fur die Morbiditat und die Mortalitat der Patienten verantwortlich. Die Lupusnephritis wird nach der Histologie in 6 Klassen eingeteilt, wobei die Klinik keine Vorhersage der Klasse erlaubt. Daher ist eine Nierenbiopsie unumganglich, da sich die Therapie nach der Klasse richtet. Wahrend bei der mesangioproliferativen Lupusnephritis (Klasse II) meist die extrarenalen Manifestationen die Therapie bestimmen, kommt man bei einer proliferativen Lupusnephritis (Klasse III fokal, Klasse IV diffus) nicht um eine Immunsuppression mit Cyclophosphamid, in letzter Zeit haufiger alternativ Mycophenolat-Mofetil (MMF), nicht herum. Bei der membranosen Glomerulonephritis (Klasse V) steht die Blockade des Renin-Angiotensin-Aldosteron (RAAS)-Systems ganz im Vordergrund. Klasse I (minimale mesangiale Lupusnephritis) und Klasse VI (Sklerose) bedurfen keiner immunsuppressiven Therapie. Neuere Therapieoptionen betreffen die B-Zell-Depletion, die Hemmung von Zytokinen oder ko-stimulatorischer Molekule und kurzlich die Inhibition des B-Lymphozyten-stimulierenden Faktors (BLyS), wobei nun erstmals ein monoklonaler Antikorper (Belimumab) beim SLE in Kombination mit der Standardtherapie zugelassen ist.
- Published
- 2012
13. Clinical Nephrology - Lab methods and other markers
- Author
-
W. Kleophas, B. Bieber, B. Robinson, J. Duttlinger, D. Fliser, G. Lonneman, L. Rump, R. Pisoni, F. Port, H. Reichel, R. Daniela, A. Ciocalteu, I. A. Checherita, I. Peride, D. M. Spataru, A. Niculae, K. Laetitia, K. Amna, D. Laurence, H.-A. Aoumeur, M. Flamant, J.-P. Haymann, E. Letavernier, E. Vidal-Petiot, J.-J. Boffa, F. Vrtovsnik, F. Bianco, G. Pessolano, M. Carraro, G. O. Panzetta, N. Ebert, J. Gaedeke, O. Jakob, M. Kuhlmann, P. Martus, M. Van der Giet, E. Scha ner, I. Khan, Y. Law, K. Turgutalp, O. Ozhan, E. Gok Oguz, A. Kiykim, C. Donadio, Z. N. Hatmi, M. Mahdavi-Mazdeh, E. Morales, V. Gutierrez-Millet, J. Rojas-Rivera, A. Huerta, E. Gutierrez, E. Gutierrez-Solis, N. Polanco, J. Caro, E. Gonza z, M. Praga, M. Marco Mayayo, J. Valdivielso, M. Marti z, E. Fernaez Giraez, G. Obrador, N. Olvera, D. Ortiz de la Pe, V. Gutie ez, A. Villa, B. Redal-Baigorri, K. Sombolos, D. Tsakiris, J. Boletis, D. Vlahakos, K. Siamopoulos, V. Vargiemezis, P. Nikolaidis, C. Iatrou, E. Dafnis, C. Argyropoulos, K. Xynos, D. Schock-Kusch, Y. Shulhevich, S. Geraci, J. Hesser, D. Stsepankou, S. Neudecker, S. Koenig, F. Hoecklin, J. Pill, N. Gretz, F. Schweda, A. Schreiber, K. Kudo, T. Konta, S. O. Choi, J. S. Kim, M. K. Kim, J. W. Yang, B. G. Han, P. Delanaye, E. Cavalier, I. Masson, M. Mehdi, M. Nicolas, B. Lambermont, B. Dubois, P. Damas, J.-M. Krzesinski, J. Morel, A. Lautrette, M. Christophe, A. Gagneux-Brunon, F. Anne, L. Fre (C)ric, S. Bevc, R. Ekart, R. Hojs, M. Gorenjak, L. Puklavec, N. Hashimoto, A. Suzuki, K. Mitsumoto, M. Shimizu, K. Niihata, A. Kawabata, Y. Sakaguchi, T. Hayashi, T. Shoji, N. Okada, Y. Tsubakihara, T. Hamano, C. Nakano, N. Fujii, Y. Obi, S. Mikami, K. Inoue, I. Matsui, Y. Isaka, H. Rakugi, V. Edvardsson, B. Siguron, M. Thorsteinsdottir, R. Palsson, J. Matsumoto, N. Miyazaki, I. Murata, G. Yoshida, K. Morishita, H. Ushikoshi, K. Nishigaki, S. Ogura, S. Minatoguchi, U. Werneke, M. Ott, E. Salander-Renberg, D. Taylor, B. Stegmayr, S. Surel, M. Wenzlova, G. Silva Junior, A. P. Vieira, A. Couto Bem, M. Alves, A. Torres, G. Meneses, A. Martins, A. Liborio, E. Daher, G. Gluhovschi, M. Modilca, L. Daminescu, C. Gluhovschi, S. Velciov, L. Petrica, F. Gadalean, C. Balgradean, H. H. Schmeiser, M. Kolesnyk, N. Stepanova, L. Surzhko, N. Stashevska, V. Filiopoulos, D. Hadjiyannakos, D. Arvanitis, K. Panagiotopoulos, D. Vlassopoulos, N. Kaesler, T. Schettgen, E. Magdeleyns, V. Brandenburg, C. Vermeer, J. Floege, T. Kr, O. Randone, M. Ferraresi, E. Aroasio, A. Depascale, S. Scognamiglio, V. Consiglio, G. B. Piccoli, L. V. Jensen, S. Lizakowski, P. Rutkowski, L. Tylicki, M. Renke, B. Sulikowska, R. Donderski, R. Bednarski, Z. Heleniak, M. Przybylska, J. Manitius, B. Rutkowski, L. Bobrova, N. Kozlovskaya, K. Kanayama, M. Hasegawa, F. Kitagawa, J. Ishii, Y. Yuzawa, K. Tanaka, K. Sakai, S. Hara, Y. Suzuki, Y. Tanaka, A. Aikawa, F. Hinoshita, N. Hamano, E. Sasaki, A. Kato, T. Katsuki, A. Katsuma, E. Imai, M. Shibata, M. Tada, T. Shimbo, Y. Kikuchi, S. Oka, T. Muramatsu, N. Yanagisawa, K. Fukutake, Y. Yamamoto, A. Ajisawa, K. Tsuchiya, K. Nitta, M. Ando, X. Liang, P. Wang, Z. Liu, Z. Zhao, V. Luyckx, S. Bowker, A. Miekle, E. Toth, R. Heguilen, A. Malvar, R. Hermes, L. Cohen, G. Muguerza, B. Lococo, A. Bernasconi, O. Loboda, I. Dudar, V. Krot, V. Alekseeva, M. Ichinose, N. Sasagawa, K. Toyama, A. Saito, Y. Kayamori, D. Kang, H. W. Kim, K. Yoshioka, M. Hara, K. Ohashi, A. Maksudova, T. Khalfina, A. Cuoghi, E. Bellei, M. Caiazzo, S. Bergamini, G. Palladino, E. Monari, A. Tomasi, E. Loiacono, R. Camilla, V. Dapr, L. Morando, R. Gallo, L. Peruzzi, M. Conrieri, M. Bianciotto, F. M. Bosetti, R. Coppo, L. DI Lullo, F. Floccari, R. Rivera, A. Granata, R. Faiola, C. Feliziani, A. Villani, M. Malaguti, A. Santoboni, K. Kyriaki, J. Droulias, M. Bogdanova, V. V. Rameev, A. H. Simonyan, L. V. Kozlovskaya, M. R. Altiparmak, S. Trabulus, N. Akalin, A. S. Yalin, A. Esenkaya, S. F. Yalin, K. Serdengeae(C), D. Arita, T. Cunha, J. Perez, M. Sakata, L. Arita, M. Nogueira, Z. Jara, N. Souza, D. Casarini, M. Metzger, M. Vallet, A. Karras, M. Froissart, B. Stengel, P. Houillier, K. Paul, D. Kretzschmar, A. Yilmaz, B. Ba hlein, S. Titze, H.-R. Figulla, G. Wolf, M. Busch, Y. Korotchaeva, N. Gordovskaya, L. Kozlovskaya, K. P. Ng, P. Sharma, S. Stringer, M. Jesky, M. Dutton, C. Ferro, P. Cockwell, S. J. Moon, S. C. Lee, S. Y. Yoon, J. E. Lee, S. J. Han, B. Anna, T. Kirsch, L. Svjetlana, P. Joon-Keun, B. Jan, K. Johanna, H. Haller, M. Haubitz, A. Smirnov, I. Kayukov, N. Rafrafi, O. Degtereva, V. Dobronravov, M. Koch, H. Stefan, G. Dika, M.-H. Antoine, C. Husson, J. Kos, M. Milic, M. Fucek, D. Cvoriocec, M.-F. Bourgeade, J. L. Nortier, B. Jelakovic, E. H. Nawal, M. Naoufal, M. Nabila, E. M. Fadwa, E. K. Salma, B. Nisrine, Z. Mohamed, M. Guislaine, B. Mohamed Gharbi, R. Benyounes, G. G. Sotila, R. Sorin, D. Irina Magdalena, C. Roxana, R. Claudia, F. Correa Barcellos, P. H. Hallal, M. Bohlke, F. Boscolo Del Vechio, A. Reges, I. Santos, G. Mielke, M. Fortes, B. Antunez, M. Laganovic, I. Vukovic Lela, S. Karanovic, J. Seric, V. Premuic, M. Fitrek, L. Fodor, T. Meljkovic Vrkic, V. Bansal, D. Hoppensteadt, and J. Fareed
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Medicine ,Medical physics ,Clinical nephrology ,business - Published
- 2012
14. Vaskulitiden
- Author
-
M. Haubitz
- Subjects
Nephrology - Abstract
Die Einteilung und Nomenklatur der Vaskulitiden wurde in der Chapel-Hill-Konsensuskonferenz 2012 erheblich geandert bzw. aktualisiert. Bei der Pathogenese der ANCA-assoziierten Vaskulitis sind die Modelle komplexer geworden. Genetische Faktoren und infektiose Trigger spielen neben B- und T-Zell-Response, endothelialen Veranderungen und dem Komplementsystem eine Rolle. Hauptplayer bleiben die Neutrophilen und neu ihre NETs („neutrophil extracellular traps“), die zur Komplementaktivierung und zur Autoantigenprasentation fuhren, sowie die B-Zellen mit den ANCA. Bei der Therapie spielen die Aktivitatsstadien eine erhebliche Rolle. Beim lokalisierten oder fruh systemischen Stadium kommt bei normaler Nierenfunktion Methotrexat mit Steroiden in Betracht. Im generalisierten Stadium kann Cyclophosphamid i. v. oder Rituximab – beide gemeinsam mit Steroiden – zur Induktionstherapie verwendet werden. Mycophenolat-Mofetil (MMF) ist nicht gleichwertig (weniger Remissionen, mehr Rezidive). Bei schwerer Nierenbeteiligung oder anderem Organversagen sind zusatzlich zu i. v. Steroidpulsen und Cyclophosphamid (wahrscheinlich ist auch Rituximab moglich, Datenlage aber dunn) Plasmapheresen indiziert. Bei der Remissionserhaltung ist Azathioprin besser als MMF, wobei eine langere Therapie zu weniger Rezidiven fuhrt. Besonders Patienten mit PR3-ANCA, Granulomen und kurzer Cyclophosphamid- und Steroidtherapie sind rezidivgefahrdet. Rituximab hat sich nach Cyclophosphamid-Induktion bei der Erhaltungstherapie Azathioprin uberlegen gezeigt (Cave: „off-label“). Die Frage der Anschlusstherapie nach erfolgreicher Rituximab-Induktion ist noch nicht geklart. Neben keiner Therapie und Reinduktion bei Rezidiv kommen eine Anschlussbehandlung mit Azathioprin, eine praemptive Rituximab-Gabe (z. B. alle 4–6 Monate fur 2 Jahre oder fur immer – „off-label“) oder die Gabe von Rituximab bei Rezidivgefahr in Betracht. Hier mussen jedoch erst verlassliche Marker gefunden werden.
- Published
- 2011
15. Mögliche Ansätze für eine gute Transition
- Author
-
M. Haubitz and L. Pape
- Subjects
Gynecology ,medicine.medical_specialty ,Transplant surgery ,Nephrology ,business.industry ,Cost analysis ,Medicine ,Chronic renal insufficiency ,business - Abstract
Ziele der Transition von der Padiatrie zur Erwachsenenmedizin sind, einen bestmoglichen Gesundheitszustand und das groste Potential fur die Patienten zu erreichen, aber auch, ihre Selbstbestimmung, ihre Entscheidungs- und Kommunikationsfahigkeit zu fordern fur eine grostmogliche Unabhangigkeit und Lebensfreude. Der Transitionsprozess muss fruhzeitig begonnen werden und chronologisches Alter, Gesundheitszustand, korperliche Reife sowie psychosoziale Aspekte berucksichtigen. Dafur notwendig sind ein Transitionsteam, ein individuell festgelegter Transitionsplan, gemeinsame Sprechstunden sowie Besprechungen und Schulungskonzepte. Eine Evaluation des Transitionserfolges ist wichtig. Einige vielversprechende Ansatze, z. B. das Transferprogramm „Endlich Erwachsen“ oder computergestutzte Schulungsmodelle wie „OTIS“, bestehen bereits. Dauerhaft kann eine erfolgreiche Transition in einem Team aus Padiatern, Internisten, Psychologen, Sozialarbeitern und Schwestern nur dann erfolgen, wenn die Finanzierung dieses Aufwandes durch die Krankenkassen gesichert wird. Dies tragt beispielsweise nach einer Nierentransplantation zu einem besseren Transplantatuberleben mit langerer Unabhangigkeit von einer chronischen Nierenersatztherapie bei.
- Published
- 2011
16. Cholesterinembolisation
- Author
-
M. Haubitz
- Subjects
Nephrology ,Internal Medicine - Published
- 2009
17. Granulomatöse ANCA-assoziierte Vaskulitiden
- Author
-
M. Haubitz and O. Wiesner
- Subjects
Pulmonary and Respiratory Medicine ,Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,business ,Wegener granulomatose - Abstract
Die Wegener-Granulomatose (WG) ist primar gekennzeichnet durch das Vorhandensein einer Vaskulitis der kleinen Arterien und Venen in Kombination mit meist zentral nekrotisierenden Granulomen. Die haufigsten Manifestationsorte sind der HNO-Bereich, die Lunge und Nieren, obwohl eine Vielzahl weiterer Organsysteme involviert sein kann. Aufgrund des immer noch toxischen Therapieregimes ist eine sichere Diagnosestellung mittels Biopsie unerlasslich. Hilfreich zur Differenzierung gegenuber anderen Vaskulitiden ist der zusatzliche Nachweis von ANCA mit Proteinase-3 als Zielantigen (c-ANCA). Die Behandlung der WG sollte neben der Erkrankungsschwere die Organmanifestation, das Alter sowie individuelle Risikofaktoren des Patienten mit einbeziehen. Fur die anstehende Remissionsinduktion werden die Patienten nach limitierter oder generalisierter Erkrankung sowie anhand des Schweregrades einer bestehenden Niereninsuffizienz eingeteilt. Wahrend MTX und Steroide fur Patienten mit limitierter Form und noch normaler Nierenfunktion meist ausreicht, bildet Cyclophosphamid in Kombination mit Prednisolon weiterhin den Standard. In besonders schweren Fallen oder bei hohen Rezidivraten steht inzwischen eine Vielzahl von Therapiealternativen zur Verfugung.
- Published
- 2008
18. Klinik und Therapie der AL-Amyloidose
- Author
-
M. Haubitz and D. Peest
- Subjects
Gynecology ,medicine.medical_specialty ,Transplant surgery ,Nephrology ,business.industry ,Medicine ,business - Abstract
Die AL-Amyloidose ist eine monoklonale Plasmazellerkrankung, bei der Immunglobulinleichtketten oder Fragmente extrazellular im Gewebe zu Amyloidfibrillen vernetzt abgelagert werden. Mit Ausnahme des Zentralnervensystems konnen alle Organe betroffen und somit funktionsgestort sein. Am haufigsten befallen sind die Nieren, initial oft mit nephrotischem Syndrom, spater auch mit renaler Funktionseinschrankung. Viele Patienten sind aufgrund der Ablagerungen in den Gefasen und im Herz hypotensiv. Die Behandlung zielt auf eine weitgehende Elimination der monoklonalen Plasmazellen, um ein Fortschreiten der Amyloidablagerungen zu verhindern oder wenigstens zu verlangsamen. Alter, Organfunktionen und andere Kriterien werden zur Patientenselektion fur aggressive oder weniger belastende Behandlungsformen genutzt, um die therapieassoziierte Mortalitat moglichst niedrig zu halten. Trotzdem ist die Prognose unbefriedigend. Deshalb ist es notwendig, neue Medikamente und experimentelle Therapieformen in klinischen Studien weiter zu entwickeln, und nach Ansatzen zu suchen, die eine Ruckbildung der Ablagerungen ermoglichen konnten.
- Published
- 2008
19. Rituximab
- Author
-
M. Haubitz
- Subjects
Nephrology - Published
- 2008
20. Interdisziplinärer deutscher Konsensus zum Management der Lupusnephritis
- Author
-
M. Haubitz and K. de Groot für die Deutsche ad hoc Lupusnephritis-Konsensusgruppe
- Subjects
Nephrology ,Internal Medicine - Published
- 2007
21. [B-cell targeted therapy in patients with granulomatosis with polyangiitis and microscopic polyangiitis]
- Author
-
F, Moosig, P-M, Aries, K, de Groot, M, Haubitz, B, Hellmich, C, Iking-Konert, A D, Wagner, and M, Zänker
- Subjects
Antibodies, Monoclonal, Murine-Derived ,B-Lymphocytes ,Recurrence ,Granulomatosis with Polyangiitis ,Humans ,Microscopic Polyangiitis ,Comorbidity ,Plasmapheresis ,Rituximab ,Combined Modality Therapy - Published
- 2014
22. Systemerkrankungen
- Author
-
M. Haubitz and U. Heemann
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Medicine ,business ,Dermatology - Published
- 2016
23. [Resistant arterial hypertension and a prominent sternum in a 77-year-old woman]
- Author
-
J, Hildebrand, M, Haubitz, A, Hertel, and P, Benöhr
- Subjects
Diagnosis, Differential ,Treatment Outcome ,Hypertension ,Humans ,Female ,Pheochromocytoma ,Thoracic Neoplasms ,Aged - Abstract
The case of a 77-year-old woman who was admitted with resistant arterial hypertension is reported. In view of a history of pheochromocytoma 2 years ago, catecholamine levels were examined and found to be elevated; in addition, MIBG scintigraphy showed a positive area in the anterior mediastinum. Computer tomography showed a tumor in the sternum. Histology confirmed metastasis from the pheochromocytoma, and the corpus was removed surgically. Currently, the patient is without any evidence of relapse.
- Published
- 2014
24. [Long-term data from the CYCLOPS study]
- Author
-
M, Haubitz
- Subjects
Adult ,Aged, 80 and over ,Male ,Vasculitis ,Adolescent ,Prednisolone ,Remission Induction ,Administration, Oral ,Middle Aged ,Drug Administration Schedule ,Antibodies, Antineutrophil Cytoplasmic ,Young Adult ,Glomerulonephritis ,Treatment Outcome ,Pulse Therapy, Drug ,Humans ,Drug Therapy, Combination ,Female ,Cyclophosphamide ,Immunosuppressive Agents ,Aged ,Glomerular Filtration Rate ,Randomized Controlled Trials as Topic - Published
- 2013
25. Influence of a novel rapamycin analogon sdz rad on endothelial tissue factor and adhesion molecule expression
- Author
-
M Haubitz and R Brunkhorst
- Subjects
Umbilical Veins ,Endothelium ,Cell Survival ,Vascular Cell Adhesion Molecule-1 ,Biology ,Umbilical vein ,Cell Line ,Thromboplastin ,Tissue factor ,medicine ,Humans ,Everolimus ,Sirolimus ,Transplantation ,Cell adhesion molecule ,Biological activity ,Adhesion ,Cell biology ,Endothelial stem cell ,medicine.anatomical_structure ,Cell culture ,Immunology ,Surgery ,Endothelium, Vascular ,E-Selectin ,Cell Adhesion Molecules ,Immunosuppressive Agents - Published
- 2002
26. EHEC Erkrankung mit HUS, akutem Nierenversagen und neurologischen Symptomen im II. Trimenon – Case-Report
- Author
-
L Spätling, T Neumann-Haefelin, M Haubitz, and D Jaspersen
- Subjects
Maternity and Midwifery ,Pediatrics, Perinatology and Child Health ,Obstetrics and Gynecology - Published
- 2011
27. Hypercalcemia and pneumocystis Pneumonia after kidney transplantation: report of an exceptional case and literature review
- Author
-
C, Chatzikyrkou, C, Clajus, M, Haubitz, and C, Hafer
- Subjects
Male ,Pneumonia, Pneumocystis ,Hypercalcemia ,Humans ,Middle Aged ,Pneumocystis carinii ,Kidney Transplantation - Abstract
Pneumocystis jirovecii remains an important pathogen in solid organ transplant recipients. Although the overall incidence may be decreasing, after the adoption of effective prophylactic measures, the risk has not been abolished, and pneumocystis pneumonia (PCP) can be observed even many years after successful transplantation. Hypercalcemia develops frequently after renal transplantation and is commonly associated with preexisting secondary hyperparathyroidism. But the pathogenesis of hypercalcemia occurring later in the course of transplantation may be different, and other disease states, such as malignancy and opportunistic infections, must be considered. Hypercalcemia in conjunction with PCP is being increasingly reported in renal transplant patients. In all the cases, respiratory symptoms were prominent, hypercalcemia was of mild-to-moderate severity, parathyroid hormone concentration was decreased, and 1,25(OH)(2) D levels were extraordinarily or inappropriately high. We report the first case to our knowledge of severe hypercalcemia accompanying PCP, in a patient with previous total parathyroidectomy.
- Published
- 2011
28. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection
- Author
-
R. Brunkhorst, O. K. Eberhardt, M. Haubitz, and F. M. Brunkhorst
- Subjects
Critical Care and Intensive Care Medicine - Published
- 2000
29. Fish, flesh and a good red herring: a case of ascending upper limb infection in a renal transplant patient
- Author
-
S, Lovric, J U, Becker, D, Kayser, A, Wagner, M, Haubitz, and J T, Kielstein
- Subjects
Diagnosis, Differential ,Immunocompromised Host ,Gout ,Mycobacterium marinum ,Humans ,Mycobacterium Infections, Nontuberculous ,Female ,Skin Diseases, Bacterial ,Middle Aged ,Kidney Transplantation - Abstract
While newly developed potent immunosuppressive agents have dramatically reduced the incidence of rejection of transplanted organs, they have increased the patients' susceptibility to opportunistic infections and cancer. Here we report a rare skin infection caused by atypical mycobacterium marinum in a 50-year-old female renal transplant recipient. The patient presented with localized skin lesion on the dorsum of her hand, which was misdiagnosed as gout. Only after the lesions spread in a sporotrichoid pattern, a cutaneous infection with atypical mycobacteria was suspected. The diagnosis was based on histopathological analysis as well as mycobacterial culture, both showing infection with atypical mycobacterium. Three months of antimycobacterial treatment led to a marked regression of the lesions. Sporotrichoid lesions in renal transplant patients are rare and a diagnostic challenge for the physician. A thorough history and a low threshold for skin biopsies could prevent painful and unnecessary surgical interventions.
- Published
- 2009
30. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection
- Author
-
R, Brunkhorst, O K, Eberhardt, M, Haubitz, and F M, Brunkhorst
- Subjects
Adult ,Calcitonin ,Male ,Vasculitis ,Calcitonin Gene-Related Peptide ,Enzyme-Linked Immunosorbent Assay ,Bacterial Infections ,Middle Aged ,Sensitivity and Specificity ,Antibodies, Antineutrophil Cytoplasmic ,Diagnosis, Differential ,Humans ,Lupus Erythematosus, Systemic ,Female ,Protein Precursors ,Biomarkers - Abstract
To investigate whether serum procalcitonin (PCT) levels could be useful to differentiate between systemic infection and the activity of the underlying disease in autoimmune disease.In 18 patients with systemic lupus erythematodes (SLE) and 35 patients with systemic antineutrophil cytoplasmic antibody-associated vasculitis (AAV) clinical disease activity was assessed by score systems. Infection was defined by clinical and microbiological means. PCT was determined in parallel with concentrations of neopterin, interleukin-6 (IL-6), and C-reactive protein (CRP) in 397 serum samples.Only in 3 of the 324 samples taken from patients with autoimmune disease but without concomitant infection, serum PCT levels were above the normal range (0.5 ng/ml), whereas neopterin, CRP and IL-6 were elevated in patients with active underlying disease. All systemic infections (N=16 in AAV-patients) were associated with markedly elevated PCT-levels (mean+/-SD:1.93+/-1.19 ng/ml).PCT may serve as a useful marker for the detection of systemic bacterial infection in patients with autoimmune disease.
- Published
- 2008
31. Circulating levels of ghrelin and leptin in ANCA-associated vasculitis
- Author
-
H Haller, Rüdiger Horn, M Haubitz, M Mengel, Georg Brabant, and Philipp Kümpers
- Subjects
medicine.medical_specialty ,Endocrinology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Leptin ,Internal medicine ,Internal Medicine ,medicine ,Ghrelin ,ANCA-Associated Vasculitis ,General Medicine ,business - Published
- 2007
32. Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides
- Author
-
S, Borgmann and M, Haubitz
- Subjects
Vasculitis ,Myeloblastin ,Serine Endopeptidases ,Humans ,Genetic Predisposition to Disease ,Prognosis ,Antibodies, Antineutrophil Cytoplasmic ,Peroxidase - Abstract
Wegener's granulomatosis (WG), microscopic polyangiitis (MPA) and the Churg-Strauss syndrome (CSS) are small vessel vasculitides associated with anti-neutrophil cytoplasmic antibodies (ANCA). Cytoplasmic (c)-ANCA mainly target proteinase 3 (PR3) and are often observed in WG patients, while perinuclear (p)-ANCA predominantly bind to myeloperoxidase (MPO) and are common in patients with MPA and CSS. It is suspected that a genetic background contributes to disease formation since the diseases are more prevalent in Caucasian populations. This article provides a detailed review of the genetic impact of the pathogenesis and prognosis of ANCA-associated vasculitides. Alpha-1 anti-trypsin is the physiological inhibitor of PR3 and carriage of the defective allele PI*Z was observed as the first genetic risk factor for the development of PR3-ANCA-associated vasculitis. Expression analyses have revealed that PR3 surface expression is genetically determined. Elevated levels of PR3 expression have been observed in WG patients and high levels of PR3 expression corresponded to increased risk of disease relapses. Furthermore, the non-carriage of CTLA-4 allele 86 was associated with WG formation, while homocygotic carriage of the CCR5 allele delta 32 seemed to prevent ANCA-negative WG. MPO-ANCA vasculitides were associated with certain alleles of CD18 polymorphisms. Lack of or only weak allelic associations of ANCA-vasculitides with polymorphic cytokine, HLA, and Fcgamma receptor genes have been shown. Although, in practice, it is sometimes difficult to differentiate between WG and MPA, the diseases appear to be based on different genetic backgrounds.
- Published
- 2005
33. Renal vasculitis
- Author
-
L. Manenti, L. Signorini, E. Gnappi, F. P. Pilato, A. Vaglio, L. Allegri, C. Buzio, A. Bertram, S. Lovric, J.-K. Park, J. U. Becker, M. Haubitz, T. Kirsch, E. Jancova, Z. Hruskova, V. Lanska, L. Sedova, R. Olsanska, D. Jilek, P. Nemejc, V. Tesar, F. Maritati, M. Urban, E. Oliva, F. Alberici, R. Smith, R. Jones, D. Jayne, Z. Chocova, H. Mareckova, B. Svobodova, V. Bednarova, and R. Rysava
- Subjects
Transplantation ,Nephrology - Published
- 2013
34. Transitionsnephrologie
- Author
-
M. Haubitz and Dirk E. Müller-Wiefel
- Subjects
Gynecology ,Nephrology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Medicine ,business - Published
- 2011
35. Aktuelles rund um die Dialyse
- Author
-
M. Haubitz and W. Kleophas
- Subjects
Nephrology ,medicine.medical_specialty ,Transplant surgery ,business.industry ,Internal medicine ,General surgery ,medicine ,business ,Angiology - Published
- 2014
36. Endothelial tissue factor stimulation by proteinase 3 and elastase
- Author
-
H. J. Kruse, M. Haubitz, R. Brunkhorst, and M. Gerlach
- Subjects
Vasculitis ,Proteases ,medicine.medical_specialty ,Myeloblastin ,Sialoglycoproteins ,Immunology ,Gene Expression ,Stimulation ,Biology ,Umbilical vein ,Antibodies, Antineutrophil Cytoplasmic ,Thromboplastin ,Rheumatic Disease/Vasculitis ,Tissue factor ,Proteinase 3 ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,cardiovascular diseases ,RNA, Messenger ,Cells, Cultured ,Peroxidase ,Pancreatic Elastase ,Elastase ,Serine Endopeptidases ,Endothelial stem cell ,Interleukin 1 Receptor Antagonist Protein ,Endocrinology ,Myeloperoxidase ,biology.protein ,Endothelium, Vascular ,Interleukin-1 - Abstract
Summary In ANCA-associated vasculitis the activation of primed leucocytes by autoantibodies with subsequent release of proteases such as myeloperoxidase (MPO), proteinase 3 (PR3) and elastase is thought to play an important pathogenetic role. Whether these proteases contribute to the vascular lesions by stimulating the procoagulant activity of these cells is unknown. Tissue factor (TF) expression and activity were investigated in human umbilical vein endothelial cells after stimulation with MPO, PR3 and elastase. TF activity was measured using a one-stage clotting assay. Polyclonal antibodies to TF were used to prove specificity. TF mRNA was detected by reverse transcriptase-polymerase chain reaction. PR3 and elastase led to a significant increase in TF mRNA expression and increased activity. The stimulation was not mediated by IL-1. The stimulatory effect of PR3 did not depend on its proteolytic activity (no inhibition by α-1-antitrypsin), whereas the effect of elastase was blocked by α-1-antitrypsin. MPO had no effect on TF activity. These results show that PR3 and elastase stimulate TF expression in human endothelial cells. In ANCA-associated vasculitis the increased release of proteases may contribute to the development of microthrombi and consecutive necrosis.
- Published
- 2001
37. [ANCA-associated vasculitis. New concepts and strategies in therapy]
- Author
-
K, de Groot, M, Haubitz, and H, Haller
- Subjects
Vasculitis ,Granulomatosis with Polyangiitis ,Hematopoietic Stem Cell Transplantation ,Animals ,Cytokines ,Humans ,Churg-Strauss Syndrome ,Immunosuppressive Agents ,Antibodies, Antineutrophil Cytoplasmic - Published
- 2000
38. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study
- Author
-
M, Haubitz, S, Schellong, U, Göbel, H J, Schurek, D, Schaumann, K M, Koch, and R, Brunkhorst
- Subjects
Vasculitis ,Injections, Intravenous ,Granulomatosis with Polyangiitis ,Administration, Oral ,Humans ,Bone Marrow Cells ,Prospective Studies ,Cyclophosphamide ,Lupus Nephritis ,Drug Administration Schedule ,Antibodies, Antineutrophil Cytoplasmic - Abstract
There is growing concern about the toxic side effects of daily oral cyclophosphamide (CYC) treatment. Intravenous (i.v.) pulse administration of CYC has been shown to be effective in patients with systemic lupus erythematosus, but contradictory results have been reported in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.The efficacy and toxicity of i.v. pulse administration of CYC (0.75 gm/m2) versus daily oral CYC treatment (2 mg/kg body weight) were investigated in a prospective, randomized, multicenter study in patients with ANCA-associated vasculitis and renal involvement.The cumulative CYC dose was reduced by 57% in patients with i.v. pulse treatment (n = 22) compared with patients treated with daily oral therapy (n = 25). Patient survival, remission rate, time of remission, relapse rate, and outcome of renal function were not different between the 2 treatment groups. However, the rate of leukopenia (P0.01) and severe infections (P0.05 by 1-tailed test) was significantly reduced in the i.v. pulse group compared with the group receiving daily oral treatment. Moreover, gonadal toxicity was reduced in the i.v. pulse group, as indicated by significantly lower levels of follicle-stimulating hormone.This randomized study shows that i.v. CYC administration is an effective therapeutic tool with low toxicity in patients with ANCA-associated vasculitis and renal involvement.
- Published
- 1998
39. Analysis of whole-blood micro-rna profiles in PR-3-ANCA positive vasculitis
- Author
-
Jan U. Becker, M. Haubitz, Torsten Kirsch, Anna Bertram, Svjetlana Lovric, and Joon-Keun Park
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,microRNA ,medicine ,General Medicine ,Vasculitis ,medicine.disease ,business ,Whole blood ,ANCA POSITIVE - Published
- 2013
40. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency
- Author
-
M, Haubitz, G, Ehlerding, A, Beigel, U, Heuer, A E, Hemmerling, and H A, Thoma
- Subjects
Adult ,Male ,Hepatitis B virus ,Vaccines, Synthetic ,Vaccination ,Middle Aged ,Hepatitis B ,Renal Dialysis ,Risk Factors ,Humans ,Kidney Failure, Chronic ,Female ,Hepatitis B Vaccines ,Hepatitis B Antibodies ,Aged - Abstract
Patients with renal insufficiency have an increased risk of hepatitis B infection and a high probability to develop a chronic course of this disease. After hepatitis B vaccination they are known to show a low rate of seroconversion. In the present study we assessed the efficacy of a new recombinant pre-S1 and pre-S2 containing hepatitis B vaccine in 17 non-responders (anti-HBs titer 0) and 4 low-responders (anti-HBs titeror = 5 IU/ml) with chronic renal insufficiency (16 on chronic hemodialysis therapy and 5 without hemodialysis treatment). Seroconversion rate was 65% after the third and 71% after the fourth vaccination. Only minor side effects were seen. These results encourage to use the new vaccine in a larger number of patients with renal insufficiency.
- Published
- 1996
41. [Glomerulonephritis within the scope of primary systemic vasculitis]
- Author
-
M, Haubitz
- Subjects
Diagnosis, Differential ,Vasculitis ,Glomerulonephritis ,Biopsy ,Kidney Glomerulus ,Humans ,Immunoglobulins ,Complement System Proteins ,Kidney ,Kidney Function Tests ,Prognosis ,Autoimmune Diseases - Published
- 1995
42. Vaskulitis
- Author
-
M. Haubitz
- Subjects
Nephrology ,business.industry ,Medicine ,business - Published
- 2012
43. Clinical Experience with the PreS1-containing Hepatitis B Vaccine (HG-3) in Different Nonresponder Groups
- Author
-
R. Müller, M. Haubitz, Angelika E. Hemmerling, H. A. Thoma, N. Firusian, and J. Grötz
- Subjects
Hepatitis B vaccine ,biology ,Genetically engineered ,business.industry ,medicine.medical_treatment ,Hepatitis B ,Hepatitis b surface antigen ,medicine.disease ,Virology ,Immunology ,medicine ,biology.protein ,Hemodialysis ,Hb vaccine ,Seroconversion ,Antibody ,business - Abstract
Conventional hepatitis B (HB) vaccines, such as the yeast-derived S-vaccine, have some serious drawbacks with regard to efficiency, as shown by the nonresponsiveness rates seen particularly in elderly persons or immunosuppressed patients. We assessed the efficacy of a genetically engineered preS1-containing HB vaccine (HG-3) in nonresponders to the S-vaccine. HG-3 was given to 5 groups of nonresponders: (1) healthy and under 40 years (n = 60); (2) healthy and over 40 (n = 13); (3) hemodialysis patients (n = 40); (4) liver transplant patients (n = 35); and (5) heart transplant patients (n = 84). Seroconversion with HG-3 was observed in 100%, 100%, 92%, 49%, and 40% of the vaccinees in groups 1 to 5, respectively. Both antibody to hepatitis B surface antigen (anti-HBs) and anti-preS antibodies were efficiently induced in these previous nonresponders. These results indicate that HG-3 is remarkably effective in inducing antibodies in S-vaccine nonresponders, even in elderly persons or immunosuppressed patients, and also suggest that the added preS region activates T cells that help produce anti-HBs.
- Published
- 1994
44. In vitro production of interleukin-1 from blood mononuclear cells of patients on chronic hemodialysis therapy
- Author
-
M, Haubitz, B, Klöppel, G, Lonnemann, and B, Nonnast-Daniel
- Subjects
Endotoxins ,Male ,Renal Dialysis ,Radioimmunoassay ,Staphylococcus epidermidis ,Humans ,Kidney Failure, Chronic ,In Vitro Techniques ,Middle Aged ,Monocytes ,Culture Media ,Interleukin-1 - Abstract
A monocyte defect is thought to be involved in the impaired immune response in patients on regular hemodialysis therapy. As an indicator of cell function, we studied in vitro IL-1 beta production of mononuclear cells from hemodialysis patients in comparison to normal controls. Mononuclear cells were stimulated with endotoxin or Staphylococcus epidermidis in parallel with control incubations in tissue culture medium alone. Spontaneous as well as stimulated total IL-1 beta production (cell-associated plus extracellular) did not differ significantly in cells obtained from patients compared to those from normal controls. However, the relative amounts of IL-1 beta released into the cell supernatants were significantly reduced in mononuclear cells from hemodialysis patients when stimulated with endotoxin but not with Staphylococcus epidermidis. These data indicate a stimulus-dependent defect in the mechanism of IL-1 beta release. As IL-1 is necessary for T-cell activation this alteration in mononuclear cell function may play a role in the impaired cellular immunity observed in patients on chronic hemodialysis therapy.
- Published
- 1992
45. Reply
- Author
-
M. Haubitz and D. Peest
- Subjects
Transplantation ,Nephrology - Published
- 2006
46. Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B
- Author
-
Otto Götze, Martin Oppermann, Elmar Quentin, and M. Haubitz
- Subjects
Adult ,Male ,medicine.medical_treatment ,Complement factor B ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Renal Dialysis ,Drug Discovery ,Humans ,Medicine ,Complement Activation ,Genetics (clinical) ,Aged ,030304 developmental biology ,Enzyme Precursors ,0303 health sciences ,medicine.diagnostic_test ,business.industry ,Complement C5 ,Complement C3 ,General Medicine ,Acute Kidney Injury ,Middle Aged ,Molecular medicine ,3. Good health ,Complement system ,Complement (complexity) ,Immunoassay ,Immunology ,Alternative complement pathway ,Kidney Failure, Chronic ,Molecular Medicine ,Female ,Hemodialysis ,business ,Complement Factor B ,030215 immunology - Abstract
Using sensitive and highly specific enzyme-linked immunosorbent assays fragments of the complement proteins C3, C5, and factor B were quantitated in patients with renal failure. During hemodialysis on new cuprophan membranes raised levels not only of C3a, but in addition of activated C3, C5a, and Ba were demonstrated. In patients with chronic renal failure and end-stage renal disease plasma concentrations of Ba and activated C3 were markedly elevated independent of hemodialysis. This finding is taken as an indication of a continuous recruitment of the alternative pathway of complement in these patients. As the detected complement protein fragments are known to exert immune regulatory functions these findings may imply that these peptides are involved in the maintenance of the immune suppressed state in renal failure.
- Published
- 1988
47. Diagnostic role of endothelial microparticles in vasculitis.
- Author
-
U. Erdbruegger, M. Grossheim, B. Hertel, K. Wyss, T. Kirsch, A. Woywodt, H. Haller, and M. Haubitz
- Subjects
B cells ,VASCULITIS ,CELL death ,JUVENILE diseases ,LEUCOCYTES ,FLOW cytometry ,KIDNEY diseases ,DIAGNOSIS - Abstract
Objective. Endothelial cells play a central pathogenetic role in ANCA-associated small-vessel vasculitis (AAV). Circulating endothelial cells (CECs), as a marker of endothelial damage, have been shown to be elevated in vasculitis. More recently, endothelial microparticles (EMPs) were found to be increased in active childhood vasculitis. The role of EMP in adult AAV and the relationship between EMP and CEC is unclear. Patients and methods. We studied 26 patients with AAV, 12 healthy volunteers and 10 patients with IgA nephropathy as disease control. Platelet-poor plasma was ultracentrifuged. MPs were identified and enumerated with flow cytometry, Annexin V, CD62E and CD105 antibodies. Leucocyte- and platelet-derived MPs were also measured. CEC were isolated and enumerated with CD146-driven immuno-magnetic isolation. Results. EMPs are significantly elevated in patients with active vasculitis (CD62E: mean 248 MP/μl ± 198 s.d.; CD105: 121 ± 135/μl) compared with patients in remission/partial remission (CD62E: 55 ± 30/μl, P = 0.001; CD105: 16 ± 12/μl, P = 0.002) and healthy volunteers (CD62E: 66 ± 33/μl, P = 0.002; CD105: 25 ± 26/μl, P = 0.007). The MP count correlates with disease activity measured by the Birmingham Vasculitis Activity Score (BVAS) (CD62E: r = 0.703; CD105: r = 0.445, P Conclusion. EMPs are elevated in active adult AAV. EMP levels correlate with disease activity and might serve as a marker of endothelial activation and damage. Differential detection of endothelial, platelet- and leucocyte-derived MPs may provide more insight in to the pathogenesis of AAV. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
48. Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis.
- Author
-
P. Kümpers, R. Horn, G. Brabant, A. Woywodt, M. Schiffer, H. Haller, and M. Haubitz
- Subjects
ENDOTHELIAL seeding ,BLOOD plasma ,VASCULAR diseases ,IMMUNODIAGNOSIS - Abstract
Objectives. To study serum levels of leptin and ghrelin in ANCA-associated vasculitis (AAV). Methods. Thirty-seven patients with AAV (21 patients with active AAV at initial presentation and during follow-up, 16 patients with AAV in long-term remission) and 21 matched healthy controls were included. Serum levels of leptin and ghrelin were measured at 0, 6 and 12 months by radioimmunoassay. Disease activity was gauged by Birmingham Vasculitis Activity Score (BVAS), CRP and circulating endothelial cells (CECs). Results. Leptin levels were significantly lower in patients than in healthy controls (9.1 ± 6.1 vs 22.3 ± 22.4 ng/ml; P P P vs 294.8 ± 70.9 pmol/l; P P Conclusions. Active AAV is characterized by decreased serum leptin and increased serum ghrelin, both of which return to normal with successful therapy. The role of leptin and ghrelin during the pathogenesis of AAV and the effects of these peptides on endothelial cells warrant further study. [ABSTRACT FROM AUTHOR]
- Published
- 2008
49. High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder.
- Author
-
Coukos A, Saglietti C, Sempoux C, Haubitz M, Greuter T, Mittaz-Crettol L, Maurer F, Mdawar-Bailly E, Moradpour D, Alberio L, Good JM, Baerlocher GM, and Fraga M
- Subjects
- Humans, Male, Female, Cross-Sectional Studies, Middle Aged, Aged, Adult, Prevalence, Telomere genetics, Hypertension, Portal genetics, In Situ Hybridization, Fluorescence, Telomere-Binding Proteins genetics, Telomerase genetics, Telomere Shortening genetics
- Abstract
Background: Telomeres prevent damage to coding DNA as end-nucleotides are lost during mitosis. Mutations in telomere maintenance genes cause excessive telomere shortening, a condition known as short telomere syndrome (STS). One hepatic manifestation documented in STS is porto-sinusoidal vascular disorder (PSVD)., Methods: As the etiology of many cases of PSVD remains unknown, this study explored the extent to which short telomeres are present in patients with idiopathic PSVD., Results: This monocentric cross-sectional study included patients with histologically defined idiopathic PSVD. Telomere length in 6 peripheral blood leukocyte subpopulations was assessed using fluorescent in situ hybridization and flow cytometry. Variants of telomere-related genes were identified using high-throughput exome sequencing. In total, 22 patients were included, of whom 16 (73%) had short (9/22) or very short (7/22) telomeres according to age-adjusted reference ranges. Fourteen patients (64%) had clinically significant portal hypertension. Shorter telomeres were more frequent in males (p = 0.005) and patients with concomitant interstitial lung disease (p < 0.001), chronic kidney disease (p < 0.001), and erythrocyte macrocytosis (p = 0.007). Portal hypertension (p = 0.021), low serum albumin level (p < 0.001), low platelet count (p = 0.007), and hyperbilirubinemia (p = 0.053) were also associated with shorter telomeres. Variants in known STS-related genes were identified in 4 patients with VSTel and 1 with STel., Conclusions: Short and very short telomeres were highly prevalent in patients with idiopathic PSVD, with 31% presenting with variants in telomere-related genes. Telomere biology may play an important role in vascular liver disease development. Clinicians should consider measuring telomeres in any patient presenting with PSVD., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
- Published
- 2024
- Full Text
- View/download PDF
50. Comparison of the hemoglobin variability in non-chronic kidney disease or end-stage renal disease participants and patients with CKD and ESRD.
- Author
-
Plappert C, Müller HJ, Haubitz M, Höcker R, Weißer H, and Benöhr P
- Subjects
- Humans, Retrospective Studies, Hemoglobins analysis, Renal Dialysis, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Erythropoietin therapeutic use, Renal Insufficiency, Chronic therapy, Renal Insufficiency, Chronic drug therapy, Anemia drug therapy, Anemia etiology
- Abstract
Introduction: Hemoglobin (Hb) variability occurs frequently in hemodialysis (HD) patients during erythropoietin (EPO) therapy. Guidelines define a narrow target range for the anemia treatment in these patients that is difficult to adhere to in practice. Our aim was to evaluate whether the Hb variability in HD patients is higher compared to non-chronic kidney disease or end-stage renal disease (ESRD) participants and patients with CKD stage I or II., Materials and Methods: Monthly blood samples were assessed prospectively in 100 non-CKD or ESRD participants and 57 patients with CKD stage I or II, and retrospectively in 74 HD patients without changes in EPO or iron dose for 6 months. Variability was calculated and compared between the different groups., Results: Hb variability was significantly higher in HD patients compared to the other groups, corresponding to results of previous studies. There were no significant differences between non-CKD or ESRD participants and patients with CKD stage I or II in terms of standard deviation (SD), residual SD, fluctuations across threshold, Hb cycling, and mean absolute change of Hb every 30 days (p > 0.05), but a significant difference compared to HD patients (p < 0.001). There were no significant differences between the groups in time in target and area under the curve (AUC) (p > 0.05)., Conclusion: Hb variability is a common phenomenon in all groups independently of the method used for assessment and even without EPO therapy. The target range is difficult to achieve for HD patients and should be reconsidered in the future to avoid unsettling both the patients and the staff.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.